Zacks Investment Research
18 Jun 2026, 11:41 UTC · 2h ago
ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
18 Jun 2026, 11:41 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Partner company uniQure N.V. announced that 3-year analysis from its Phase I/II study for the Huntington's disease candidate AMT-130 can serve as the primary basis for an FDA accelerated approval application. — The potential for accelerated FDA approval of a partner's treatment candidate is a material catalyst for ClearPoint Neuro's growth and valuation.
+0.60ClearPoint Neuro (CLPT) shares rose 26% in the last trading session to close at $16.81 on high volume. — Significant price movement on high volume indicates strong short-term momentum and investor interest.
+0.30ClearPoint Neuro is expected to report quarterly revenues of $13 million, representing a 41% increase year-over-year. — Strong revenue growth indicates expanding business scale, although the company is still expected to post a loss.
+0.20Continue reading
6 related stories
Search tags
The consensus EPS estimate for ClearPoint Neuro has remained unchanged over the last 30 days. — The lack of upward earnings revisions may limit the sustainability of the recent price rally according to the analysis.
-0.10Which stocks this story touches
Shares rallied 26% following positive regulatory milestones for a partner's treatment candidate.
The stock closed lower in the last session and has seen a negative return over the past month.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
59m ago
